Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab and Cyclosporine for Severe Aplastic Anemia
NCT00895739Phase 2Unknown
- Sponsor
- University of Naples Federico II
- Start
- Jun 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in aplastic anemia, acquired bone marrow failure (ABMF), pure red cell aplasia (PRCA), agranulocytosis, Amegakaryocytic Thrombocytopenia (CAMT), sponsored by University of Naples Federico II. Status: unknown.
02
Drugs
alemtuzumab
03
Conditions
aplastic anemiaacquired bone marrow failure (ABMF)pure red cell aplasia (PRCA)agranulocytosisAmegakaryocytic Thrombocytopenia (CAMT)
Beyond the preview
Go deeper on NCT00895739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00895739.